Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | US$664.31B | 63.2x | 0.68 | US$738.21 | -6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28% Upside | Upgrade to Pro+ | |
UnitedHealth | NYSE | Healthcare | Healthcare Providers & Services | US$480.96B | 34.1x | -0.94 | US$525.42 | -2.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.2% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | US$369.31B | 26.5x | -0.49 | US$153.24 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.1% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | US$330.43B | 78.8x | -7.06 | US$186.91 | -7.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.1% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | US$282.28B | 19.1x | 0.97 | US$62.54 | -6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | US$257.68B | 26.9x | -1.03 | US$37.65 | -5.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.7% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | US$257.68B | 26.9x | -1.03 | US$302 | -6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | US$216.75B | 31.1x | 1.8 | US$136.64 | -9.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | US$216.75B | 31.1x | 1.8 | US$68.46 | -7.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.2% Upside | Upgrade to Pro+ | |
Abbott Labs | NYSE | Healthcare | Healthcare Equipment & Supplies | US$215.98B | 16.3x | 0.13 | US$124.44 | -5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.6% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | US$205.90B | 12.2x | 0 | US$81.50 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.1% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | US$203.60B | 18.2x | -1.02 | US$104.67 | -7.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | US$203.60B | 18.2x | -1.02 | US$105.85 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2% Downside | Upgrade to Pro+ | |
Thermo Fisher Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$165.52B | 26.6x | 4.26 | US$437.91 | -6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.5% Upside | Upgrade to Pro+ | |
Intuitive Surgical | NASDAQ | Healthcare | Healthcare Equipment & Supplies | US$162.24B | 69.8x | 2.75 | US$451.58 | -8.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.7% Upside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | US$158.29B | 39x | -1.02 | US$294.26 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.2% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | US$133.68B | 286.4x | -3.17 | US$107.28 | -4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.1% Downside | Upgrade to Pro+ | |
Boston Scientific | NYSE | Healthcare | Healthcare Equipment & Supplies | US$133.15B | 71.6x | 4.71 | US$89.70 | -8.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.3% Upside | Upgrade to Pro+ | |
Stryker | NYSE | Healthcare | Healthcare Equipment & Supplies | US$132.44B | 44.3x | -7.83 | US$346.03 | -6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | US$130.50B | 16.3x | 0.06 | US$22.99 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.5% Upside | Upgrade to Pro+ | |
Danaher | NYSE | Healthcare | Healthcare Equipment & Supplies | US$130.03B | 34.5x | -2.21 | US$181.59 | -8.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.9% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | US$129.35B | 22x | 7.83 | US$51.97 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.6% Upside | Upgrade to Pro+ | |
Essilor International SA | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$122.39B | 47.3x | 52.44 | US$131.71 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -10.9% Downside | Upgrade to Pro+ | |
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | US$121.93B | -230.9x | 2.05 | US$474.62 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.8% Upside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | US$111.96B | -12.6x | 0.06 | US$55.31 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.2% Upside | Upgrade to Pro+ | |
Medtronic | NYSE | Healthcare | Healthcare Equipment & Supplies | US$106.36B | 25.4x | 6.91 | US$82.88 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
Elevance Health | NYSE | Healthcare | Healthcare Providers & Services | US$97.69B | 16.9x | 9 | US$428.89 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6% Upside | Upgrade to Pro+ | |
Cigna | NYSE | Healthcare | Healthcare Providers & Services | US$87.56B | 26.6x | -0.85 | US$322.39 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | US$85.37B | 31.4x | -23.53 | US$683.11 | -4.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.5% Downside | Upgrade to Pro+ | |
HCA | NYSE | Healthcare | Healthcare Providers & Services | US$81.95B | 15x | 0.92 | US$331.65 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8% Upside | Upgrade to Pro+ | |
CVS Health Corp | NYSE | Healthcare | Healthcare Providers & Services | US$80.20B | 17.5x | -0.42 | US$63.67 | -5.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | US$74.62B | 1.58 | US$22.46 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | US$74.43B | 22.6x | -0.49 | US$18.38 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | US$74.43B | 22.6x | -0.49 | US$36.53 | -6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | US$73.53B | 28.2x | 2.5 | US$74.44 | -7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.9% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | US$67.86B | 27.9x | 3.72 | US$151.73 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.3% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | US$61.47B | 14.2x | 1.51 | US$572.91 | -6.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Becton Dickinson | NYSE | Healthcare | Healthcare Equipment & Supplies | US$59.69B | 34.8x | 0.92 | US$207.34 | -6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | US$56.18B | 18.4x | -12.9 | US$25.33 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.6% Upside | Upgrade to Pro+ | |
Siemens Healthineers ADR | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$54.84B | 26.4x | 0.93 | US$24.07 | -5.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 33.5% Upside | Upgrade to Pro+ | |
Cencora Inc | NYSE | Healthcare | Healthcare Equipment & Supplies | US$53.98B | 39.3x | -1.63 | US$278.59 | -3.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -3.2% Downside | Upgrade to Pro+ | |
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | US$46.73B | 25x | 0.63 | US$9.89 | -5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.1% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | US$46.62B | 33.9x | 2.15 | US$30.07 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | US$46.62B | 33.9x | 2.13 | US$14.73 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.4% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | US$46.24B | 28.3x | 0.85 | US$24 | -1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | US$43.12B | 58x | US$58.86 | -5.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.1% Upside | Upgrade to Pro+ | ||
Alcon | NYSE | Healthcare | Healthcare Equipment & Supplies | US$41.42B | 41x | 10.13 | US$83.82 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.5% Upside | Upgrade to Pro+ | |
Edwards Lifesciences | NYSE | Healthcare | Healthcare Equipment & Supplies | US$40.85B | 29.8x | 0.15 | US$69.38 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.6% Upside | Upgrade to Pro+ | |
Hoya Corp | OTC Markets | Healthcare | Healthcare Equipment & Supplies | US$36.66B | 26.4x | 1.12 | US$100.84 | -3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.3% Upside | Upgrade to Pro+ | |
Veeva Systems A | NYSE | Healthcare | Healthcare Equipment & Supplies | US$34.83B | 48.6x | 1.56 | US$213.68 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ |